IL23A and psoriasis: It is known that IL-17 is located downstream of IL-23 in the pathogenesis of psoriasis [23] and therefore, treatment of psoriasis by antagonizing IL-17 may be more prone to relapse than blocking IL-23, thus requiring patients to take the drug more frequently [24].